Unraveling m6A RNA methylation: From epitranscriptomics to therapeutic frontiers in renal cell carcinoma.

N6-methyladenosine (m6A) RNA methylation has emerged as a crucial regulatory mechanism in cancer biology, influencing processes such as RNA splicing, stability, translation, and degradation. Renal cell carcinoma (RCC), often referred to as a silent cancer, is one of the most common malignancies of the urinary tract and is associated with poor prognosis and inadequate treatment options. m6A modifications play a pivotal role in RCC tumorigenesis, metastasis, progression, immune response modulation, and therapy resistance. This review provides a comprehensive overview of the current understanding of m6A in RCC, discussing key m6A regulators and their roles as potential biomarkers and therapeutic targets. Furthermore, we explore advanced technologies like single-cell omics and machine learning in elucidating the role of m6A in RCC, facilitating the search for effective therapeutic targets. Future directions focus on translating these findings into clinical applications, with a view toward personalized medicine and combination therapies.